October 24, 2016 3:13 PM ET


Company Overview of Grupo J Uriach S.L.

Company Overview

Grupo J Uriach S.L., together with its subsidiaries, engages in the research, development, manufacture, marketing, and export of pharmaceutical products. The company operates in five business units: Uriach Pharma, Uriach-Aquilea OTC, Pharmagenus, Industrial Area, and Palau Pharma. The Uriach Pharma business unit markets prescription pharmaceuticals derived from its own research and development, and licensed from other multinationals. It sells a range of therapeutics, including anti-platelet drugs, anti-hypertensive agents, anti-histaminics, asthma treatments, antibiotics, anti-mycotics, and anti-anemics. The Uriach-Aquilea OTC business unit provides a line of OTC products; natural products, ...

Poligono Industrial Riera de Caldes

Avinguda Cami Reial 51-57

Palau-solità i Plegamans

Barcelona,  08184


Founded in 1838


34 93 864 96 92


34 93 864 66 06

Key Executives for Grupo J Uriach S.L.

Chief Executive Officer
Managing Director, Member of Family Assembly and Member of Family Council
Chairman of Board of Administration, Secretary of Family Assembly and Secretary of Family Council
Secretary of Board of Administration
Independent Councillor of Board of Administration
Age: 61
Compensation as of Fiscal Year 2016.

Grupo J Uriach S.L. Key Developments

Pediapharm and Uriach Enter into a License and Supply Agreement for a Novel Product

Pediapharm Inc. and J. Uriach y Compañía S.A. Ltd. (Uriach) entered into an agreement to grant Pediapharm the exclusive Canadian rights to rupatadine, a novel second generation antihistamine with a broad profile of anti-inflammatory properties. Pediapharm intends to register both the adult and pediatric products for the indications: allergic rhinitis and urticaria. As a reference, rupatadine tablets are already registered and authorized in more than 70 countries while the pediatric solution is already authorized in 43 countries. In Spain and Italy, the product captured approximately 16% market share while capturing up to 27% market share in other territories. The key attributes of rupatadine based on Pediapharm's assessment are, novel potent second generation antihistamine, non-sedating, with a rapid onset of action, and once a day oral administration (tablets and pediatric solution); Unique dual activity: blocking of both histamine H1 and platelet-activating factor (PAF) receptors; thus, providing additional anti-allergic benefits to patients; Taken with or without food; No effect on driving ability at the therapeutic dose; Cardiac safety up to 10 times therapeutic dose based on results from a clinical study designed as per the ICH guidelines.

Similar Private Companies By Industry

Company Name Region
Ability Pharmaceuticals, S.L. Europe
Activery Biotech SL Europe
Aelix Therapeutics SL Europe
AlbaJuna Therapeutics SL Europe
Alcaliber S.A. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Grupo J Uriach S.L., please visit www.uriach.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.